Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi-Qi-Pin-Chuan granules is a Traditional Chinese Medicine (TCM) herbal formula developed by West China Hospital (Huaxi Hospital) at Sichuan University for the treatment of acute bronchial asthma exacerbations. As a multi-herb compound preparation, its name translates to 'benefiting Qi and calming wheezing,' reflecting its therapeutic intent in TCM theory. The formula is typically used as an add-on therapy to standard acute asthma treatments. Clinical evaluation has focused on its efficacy in patients with mild to moderate asthma exacerbations, where it is administered in granule form over a 7-day course. Like many TCM preparations, its mechanism of action is attributed to the synergistic effects of its multiple herbal components rather than a single molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yi-Qi-Pin-Chuan granules.